Tempus AI, Inc.

Tempus AI (TEM) jumped 7.4% in a single day to $72.15, recovering part of a slide that had taken it 15.2% below its September 28, 2026 peak. The weekly trend is still up and the daily trend runs with it, so the balance of evidence leans positive for the next 2–6 weeks, with medium conviction. Earnings on November 2, 2026 are the next test. A daily close above $72.98 on heavier volume would be the first sign that buyers are back.

Why it matters

The move is the story, and the news does not explain it. No company announcement, deal or analyst action sits behind the 7.4% one-day jump, and nothing in the debate around the stock points to a cause. The honest reading is that this is a price-driven rebound after a sharp drop, not a reaction to new information. That matters because rebounds without a catalyst tend to be tested quickly.

The size of the earlier fall shows what was priced in. From the September 28 close of $85.08 the shares lost 15.2%, and over the past month they are down 15.1%. Over six months they are still up 37%, and year to date they are up 22.2%. The stock has given back a large part of a strong run and has now recovered a slice of that loss. Its price is about 21.2% below the 52-week high of $91.58 and 73.7% above the low of $41.55.

Almost none of the latest five-day gain came from the market or the sector. The stock rose 8.1% over five days, while the S&P 500 (SPY) added just 0.08% and the healthcare sector fund XLV fell 0.36%. That leaves about 8.4 points of outperformance against the sector that belong to TEM alone. Over 50 days TEM leads the S&P 500 by 3.2 points but trails XLV by 1.0, so the longer record is one of a stock moving roughly with its sector, not away from it. Over 200 days it leads the market by 20.2 points.

No articles are available to set out the debate between bulls and skeptics, so the argument can only be inferred from the numbers. The 18 analysts covering the stock rate it a buy, with a mean price target of $75.06. Targets range from $35.00 to $100.00, a very wide spread that shows how little agreement there is on what the business is worth. At $72.15 the shares sit 3.9% below the mean target, so the consensus sees limited room on its own numbers, and the upside case rests on the high end of that range. The market value is about $13.1 billion.

What the evidence says

On the long term the thesis is intact but has been tested. Price is above its 40-week average, and the 50-day average at $69.7 is well above the 200-day at $56.83. That is an established uptrend in a correction phase: the stock peaked in late September, fell hard, and is now trying to rebuild. Nothing in the weekly structure is broken.

For the next 2–6 weeks the balance of evidence leans positive, and conviction is medium, 2 of 4 points. Two things support it: the daily trend runs with the weekly uptrend, and the stock leads the S&P 500 over 50 days. The other two points are missing, which is why conviction is not higher. RSI is 52.8, which is neutral and gives no oversold or momentum signal. Volume on the latest session was 18.1% below its 20-day average, so the jump came without heavy participation.

The strongest case against this reading is exactly that thin participation, together with the lag against XLV. The stock trails its sector by 1.0 point over 50 days, which is against the trend, and a 7.4% one-day jump on below-average volume is the kind of move that can fade. It does not tip the balance because price is holding above the 50-day average and the weekly trend is intact. It does cap conviction at medium until volume confirms.

Levels that matter

The structure holds above $70.0, a round number that sits next to the 50-day average at $69.7. A first crack comes below $70.0. The trend itself ends below $61.79, a swing zone that also sits above the round $60.0 and the next support at $57.88. The ATR is $5.18, so a typical daily swing is large relative to the distance between $70.0 and the current price.

The breakout level is a daily close above $72.98 on volume above its 20-day average. From there the math points to the 52-week high of $91.58, with $80.00 and $90.00 as resistance on the way. The breakout would be wrong below $68.70, which is $70.0 minus a quarter of ATR. Against that stop the target gives a reward-to-risk of 4.3 to 1, which clears the 3 to 1 that makes a breakout worth the risk.

What would change the picture

A weekly close below $61.79 would change the picture, because it would break the swing zone that defines the end of the uptrend and put price under the lows of the current correction. The non-price fact that would do it is earnings: a result that forces a reset of expectations, with the stock already well off its highs, would be the likeliest trigger. A clean result that holds the rebound would instead strengthen the positive reading.

What to watch

• Earnings on November 2, 2026: the number that matters is how the shares react relative to the $70.0 area. A close back under it would be the first crack.
• Healthcare sector moves in XLV, which fell 0.36% over five days. The stock trails the sector over 50 days, so sector direction can move TEM before any company news does.
• Volume on any push through $72.98: it needs to be above the 20-day average to count as a breakout.
• Valuation: at $72.15 the stock is 3.9% below the $75.06 mean target, with analyst targets spread from $35.00 to $100.00.